GRACE – Global Resource for Advancing Cancer Education Published on Dec 5, 2018 Drs. H. Jack West, Medical Director -…
Browsing: Small Cell Lung Cancer
Luis G. Paz-Ares, MD, PHD will be presenting Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from…
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy…
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory…
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small…
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard…
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses…
Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Whats On Deck For Lurbinectedin. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Upcoming SCLC Data. At ESMO Oncology Conference – Munich, Germany On October…
Pascal Besman Chief Operating Officer at PharmaMar discusses Progress In SCLC Vs. NSCLC. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Lurbinectedin Data Presented This Year. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses IO Likely In 1st Line SCLC. At ESMO Oncology Conference – Munich,…
Pascal Besman Chief Operating Officer at PharmaMar discusses Current Standard Of Care In SCLC. At ESMO Oncology Conference – Munich,…
Pascal Besman Chief Operating Officer at PharmaMar Discusses Differences Between NSCLC & SCLC. At ESMO Oncology Conference – Munich, Germany…
Treatment options for small cell lung cancer (SCLC) have not advanced significantly in the past few decades, and patients with…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains CaM6 In Collaboration w German Cancer Ctr. | ILDR2 In Collaboration w Compugen…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Thorium Platform Based on Initial Radium (Xofigo) | Thorium Delivers Alpha Radiation at…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains DHODH Inhibitor Pyrimidine Synthesis | FGFR Inhibitor has Response Rate of 24% at…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor at Annual…
Ana Limon Carrera, Takeda Oncology, Additional Cell-Cycle Modulators is of Great Interest | Molecule w/ Safety Profile Combines Well with…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Submitting Update of Monotherapy to ESMO | Closure of ATLANTIS Trial…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Far Along Development in SCLC | American Oncologists Less Familiar w…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Development in Small Cell has been Much Slower | Most Drivers…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Lurbinectedin More Pronounced in Overall Survival | OS Endpoint is Preferable…
Pascal Besman, Chief Operating Officer of PharmaMar, shares Investigator Sponsored Trials in Europe & US | With Immuno-Oncology Checkpoint Inhibitors…
Pascal Besman, Chief Operating Officer of PharmaMar, shares a Randomized Trial of Topotecan & CAV | Monotherapy Will Have Up…
Pascal Besman, Chief Operating Officer of PharmaMar, shares an Update on Relapsed SCLC Monotherapy Trial | Overall Survival Data of…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD,…
Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the topic of lung cancer and that there is an entire spectrum…
Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joined GRACE to discuss…
Paul K. Paik, MD of Memorial Sloan Kettering Cancer Center discusses the PFS of FLAURA trial compared to first generation…